

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Laquinimod for treating relapsing-remitting  
multiple sclerosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the draft scope consultation, one consultee noted that the population being considered in this technology appraisal did not specify whether it included children.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Only adult patients have taken part in the clinical trials for laquinimod and therefore it is unlikely that children will be included in the marketing authorisation. The Appraisal Committee will make recommendations based on the assessment of the clinical and cost effectiveness of the technology within its licensed indication.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
---

No.
-----

**Approved by Associate Director (name):** Elisabeth George

**Date:** 29 11 13